<DOC>
	<DOCNO>NCT01454284</DOCNO>
	<brief_summary>The purpose study : - To compare blood sugar control LY2605541 insulin glargine 52 week treatment . - To compare number nocturnal low blood sugar episode LY2605541 insulin glargine 52 week treatment . - To compare number patient LY2605541 reach blood sugar target without low blood sugar episode night take insulin glargine 52 week treatment . - To compare total number low blood sugar episode LY2605541 insulin glargine 52 week treatment</brief_summary>
	<brief_title>A Study Patients With Type I Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Type 1 diabetes least 1 year HbA1c value le 12 percent accord central laboratory screen body mass index less equal 35.0 kg/m^2 Have treat least 90 day prior screen insulin detemir , insulin glargine , Neutral Protamine Hagedorn ( NPH ) combination premeal insulin , self mixed premixed insulin regimen basal bolus insulin combination administer least twice daily , continuous subcutaneous insulin infusion therapy Women breast feed test negative pregnancy receive treatment agree use reliable birth control 4 week last treatment study drug Are capable willing adhere multiple daily injection , inject vial syringe prefilled pen perform self monitor blood glucose reading record keep Are use twice daily insulin glargine inadequately control single daily dose glargine prior screen Excessive insulin resistance define received total daily dose insulin great 1.5 U/kg time randomization Receiving oral injectable medication ( insulins metformin treatment polycystic ovarian disease ) intend treatment diabetes mellitus 90 day prior screen Lipid lower medication : use niacin preparation lipid lower medication and/or bile acid sequestrants within 90 day prior screen ; , use lipid lower medication dose stable 90 day prior screen Have fast hypertriglyceridemia ( define great 4.5 mmol/L , great 400 mg/dl ) screening , determined central laboratory . Have 1 episode severe hypoglycemia within 6 month prior screen Have 2 emergency room visit hospitalization due poor glucose control within 6 month prior screen Have cardiac disease functional status New York Heart Association Class III IV Have history renal transplantation currently receive renal dialysis serum creatinine great 2.5 mg/dL Have obvious clinical sign symptom liver disease ( exclude nonalcoholic fatty liver disease [ NAFLD ] ) , acute chronic hepatitis , non alcoholic steatohepatitis ( NASH ) , elevate liver enzyme measurement indicate : total bilirubin 2 time upper limit normal ( ULN ) define central laboratory , alanine aminotransferase ( ALT ) / ( serum glutamic pyruvic transaminase ( SGPT ) 2.5 time ULN define central laboratory , aspartate aminotransferase ( AST ) / ( serum glutamic oxaloacetic transaminase ( SGOT ) 2.5 time ULN define central laboratory Have active untreated malignancy , remission clinically significant malignancy ( basal cell squamous cell skin cancer ) less 5 year , increase risk develop cancer recurrence cancer Diagnosed clinically significant diabetic autonomic neuropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>